Hemophilia A Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Hemophilia A Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major hemophilia A markets reached a value of US$ 10,288.7 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 28,447.2 Million by 2034, exhibiting a growth rate (CAGR) of 9.69% during 2024-2034.

The hemophilia A market has been comprehensively analyzed in IMARC's new report titled "Hemophilia A Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hemophilia A refers to a genetic bleeding disorder characterized by a deficiency or dysfunction of clotting factor VIII (FVIII). It is the most common type of hemophilia, accounting for approximately 80% of all cases. Some of the common symptoms associated with the ailment include prolonged bleeding after injuries, surgeries, or dental procedures; frequent nosebleeds; easy bruising; spontaneous joint or muscle bleeding; and, in severe instances, potentially life-threatening internal bleeding. Individuals suffering from hemophilia A may also experience excessive bleeding from minor cuts or trauma, as well as prolonged bleeding from the gums or gastrointestinal tract. During the diagnosis, a healthcare provider will assess the patient's medical records, family history, and symptoms suggestive of abnormal bleeding. Blood tests will also be performed to measure the levels of clotting factor VIII activity in the blood. A significantly reduced level of FVIII confirms the diagnosis of hemophilia A. In some cases, genetic testing may be conducted to identify specific mutations in the F8 gene. Additionally, various other laboratory tests, such as coagulation studies and bleeding time evaluations, are performed to assess the overall bleeding profile.

The rising cases of genetic mutations that result in a deficiency or dysfunction of clotting factor VIII, which is essential for normal blood clotting, are primarily driving the hemophilia A market. Additionally, the inflating demand for hemostatic agents, such as antifibrinolytic drugs, as adjunctive therapy to enhance clot stability and minimize bleeding is creating a positive outlook for the market. Furthermore, the escalating utilization of prophylactic treatment that involves regular infusions of clotting factor VIII to prevent or reduce the frequency and severity of bleeding is also bolstering the market growth. Besides this, the emerging popularity of extended half-life (EHL) clotting factors, since they offer the advantage of increased convenience and potentially improved protection against bleeding episodes as compared to standard clotting factors, is acting as another significant growth-inducing factor. Moreover, the rising usage of immune tolerance induction therapy, which entails high-dose and frequent infusions of FVIII over an extended period to desensitize the immune system as well as induce tolerance to FVIII, is expected to drive the hemophilia A market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the hemophilia A market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hemophilia A and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hemophilia A market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hemophilia A market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hemophilia A market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current hemophilia A marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the hemophilia A market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the hemophilia A market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the hemophilia A market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of hemophilia A across the seven major markets?
What is the number of prevalent cases (2018-2034) of hemophilia A by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of hemophilia A by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with hemophilia A across the seven major markets?
What is the size of the hemophilia A patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of hemophilia A?
What will be the growth rate of patients across the seven major markets?

Hemophilia A: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for hemophilia A drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hemophilia A market?
What are the key regulatory events related to the hemophilia A market?
What is the structure of clinical trial landscape by status related to the hemophilia A market?
What is the structure of clinical trial landscape by phase related to the hemophilia A market?
What is the structure of clinical trial landscape by route of administration related to the hemophilia A market?